deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 1-arm NCT03132792

AFPᶜ³³²T in Advanced HCC

A Phase I Open Label Clinical Trial Evaluating the Safety and Anti-Tumor Activity of Autologous T Cells Expressing Enhanced TCRs Specific for Alpha Fetoprotein (AFPᶜ³³²T) in HLA-A2 Positive Subjects With Advanced Hepatocellular Carcinoma (HCC) or Other AFP Expressing Tumor Types

Sponsor: Adaptimmune

Conditions AFP Expressing Tumors Hepatocellular Cancer
Interventions Autologous genetically modified AFPᶜ³³²T cells
Updated 20 times since 2017 Last updated: Aug 12, 2025 Started: May 8, 2017 Primary completion: Jul 7, 2021 Completion: Dec 7, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates AFP Expressing Tumors and Hepatocellular Cancer and is currently ongoing. Adaptimmune leads this study, which shows 20 recorded versions since 2017 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jun 2017 – ~Sep 2017 · 3 months · monthly snapshot~Sep 2017 – ~Nov 2017 · 2 months · monthly snapshot~Nov 2017 – ~Feb 2018 · 3 months · monthly snapshot~Feb 2018 – ~Mar 2018 · 28 days · monthly snapshot~Mar 2018 – ~Jun 2018 · 3 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Dec 2018 · 3 months · monthly snapshot~Dec 2018 – ~Feb 2019 · 2 months · monthly snapshot~Feb 2019 – ~Mar 2020 · 13 months · monthly snapshot~Mar 2020 – ~May 2020 · 2 months · monthly snapshot~May 2020 – ~Jan 2021 · 8 months · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Sep 2021 · 6 months · monthly snapshot~Sep 2021 – ~Oct 2021 · 30 days · monthly snapshot~Oct 2021 – ~Jun 2022 · 8 months · monthly snapshot~Jun 2022 – ~Sep 2022 · 3 months · monthly snapshot~Sep 2022 – ~Jul 2024 · 22 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

20 versions recorded

  1. Sep 2025 — Present [monthly]

    Active Not Recruiting PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Active Not Recruiting PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  4. Sep 2022 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

    Status: Recruiting → Active Not Recruiting

  5. Jun 2022 — Sep 2022 [monthly]

    Recruiting PHASE1

▶ Show 15 earlier versions

  1. Oct 2021 — Jun 2022 [monthly]

    Recruiting PHASE1

  2. Sep 2021 — Oct 2021 [monthly]

    Recruiting PHASE1

  3. Mar 2021 — Sep 2021 [monthly]

    Recruiting PHASE1

  4. Jan 2021 — Mar 2021 [monthly]

    Recruiting PHASE1

  5. May 2020 — Jan 2021 [monthly]

    Recruiting PHASE1

  6. Mar 2020 — May 2020 [monthly]

    Recruiting PHASE1

  7. Feb 2019 — Mar 2020 [monthly]

    Recruiting PHASE1

  8. Dec 2018 — Feb 2019 [monthly]

    Recruiting PHASE1

  9. Sep 2018 — Dec 2018 [monthly]

    Recruiting PHASE1

  10. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE1

  11. Mar 2018 — Jun 2018 [monthly]

    Recruiting PHASE1

  12. Feb 2018 — Mar 2018 [monthly]

    Recruiting PHASE1

  13. Nov 2017 — Feb 2018 [monthly]

    Recruiting PHASE1

  14. Sep 2017 — Nov 2017 [monthly]

    Recruiting PHASE1

  15. Jun 2017 — Sep 2017 [monthly]

    Recruiting PHASE1

    First recorded

May 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Adaptimmune
Data source: Adaptimmune

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Baltimore, United States , Barcelona, Spain , Boston, United States , Glasgow, United Kingdom , Houston, United States , London, United Kingdom , Los Angeles, United States , Manchester, United Kingdom , Marseille, France and 8 more locations